Track topics on Twitter Track topics that are important to you
Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced the pricing of a “best efforts” public offering of Company’s shares of common stock and warrants with expected total gross proceeds of up to $2.5 million. … Continued
The post Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering appeared first on Investing News Network.
Original Article: Nemaura Medical Announces Pricing of Up to $2.5 Million Public OfferingNEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...